K A Woeber

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Relationship between thyroid stimulating hormone and thyroid stimulating immunoglobulin in Graves' hyperthyroidism
    K A Woeber
    University of California San Francisco, Campus Box 1640, San Francisco, CA 94143 1640, USA
    J Endocrinol Invest 34:222-4. 2011
  2. ncbi Graves ophthalmopathy after radiation treatment of thyroid cancer
    Kenneth A Woeber
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 1640, USA
    Endocr Pract 14:419-21. 2008
  3. ncbi Triiodothyronine production in Graves' hyperthyroidism
    Kenneth A Woeber
    University of California San Francisco, San Francisco, California 94143, USA
    Thyroid 16:687-90. 2006
  4. ncbi Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California San Francisco UCSF, San Francisco, California 94143, USA
    Thyroid 19:953-6. 2009
  5. ncbi Observations concerning the natural history of subclinical hyperthyroidism
    Kenneth A Woeber
    University of California, San Francisco, San Francisco, California 94143 1640, USA
    Thyroid 15:687-91. 2005
  6. ncbi Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors
    Electron Kebebew
    Department of Surgery, University of California San Francisco, San Francisco, CA 94143 1674, USA
    Cancer 103:1330-5. 2005
  7. ncbi A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, CA 94143, USA
    Surgery 140:960-6; discussion 966-7. 2006
  8. ncbi Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations
    K A Woeber
    Department of Medicine, University of California, San Francisco Mount Zion, San Francisco 94143 1640, USA
    J Endocrinol Invest 25:106-9. 2002
  9. ncbi Extent of disease and practice patterns for medullary thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, San Francisco, CA 94143-1674, USA
    J Am Coll Surg 200:890-6. 2005
  10. ncbi Methimazole-induced hepatotoxicity
    Kenneth A Woeber
    Department of Medicine, University of California, San Franscisco, California 94143-1640, USA
    Endocr Pract 8:222-4. 2002

Detail Information

Publications10

  1. ncbi Relationship between thyroid stimulating hormone and thyroid stimulating immunoglobulin in Graves' hyperthyroidism
    K A Woeber
    University of California San Francisco, Campus Box 1640, San Francisco, CA 94143 1640, USA
    J Endocrinol Invest 34:222-4. 2011
    ..Accordingly, the relationship between TSH and serum thyroid stimulating immunoglobulin (TSI) was examined during follow-up of patients with Graves' hyperthyroidism...
  2. ncbi Graves ophthalmopathy after radiation treatment of thyroid cancer
    Kenneth A Woeber
    Department of Medicine, University of California San Francisco, San Francisco, California 94143 1640, USA
    Endocr Pract 14:419-21. 2008
    ..To describe a patient with metastatic thyroid cancer who developed Graves ophthalmopathy after treatment with radioiodine (I 131) and external beam radiation...
  3. ncbi Triiodothyronine production in Graves' hyperthyroidism
    Kenneth A Woeber
    University of California San Francisco, San Francisco, California 94143, USA
    Thyroid 16:687-90. 2006
    ....
  4. ncbi Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California San Francisco UCSF, San Francisco, California 94143, USA
    Thyroid 19:953-6. 2009
    ..We investigated the efficacy and side effects of rosiglitazone therapy in patients with differentiated thyroid cancer of follicular cell origin that fails to take up radioiodine or is unresectable...
  5. ncbi Observations concerning the natural history of subclinical hyperthyroidism
    Kenneth A Woeber
    University of California, San Francisco, San Francisco, California 94143 1640, USA
    Thyroid 15:687-91. 2005
    ..Seven of the patients had subclinical Graves' hyperthyroidism as judged from the presence of thyroid-stimulating immunoglobulins (TSI) in serum, and 9 had multinodular goiter confirmed with ultrasound and no TSI...
  6. ncbi Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors
    Electron Kebebew
    Department of Surgery, University of California San Francisco, San Francisco, CA 94143 1674, USA
    Cancer 103:1330-5. 2005
    ..The authors analyzed prognostic factors and treatment outcomes in patients with ATC reported in the National Cancer Institute's Surveillance, Epidemiology, and End Results data base...
  7. ncbi A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, CA 94143, USA
    Surgery 140:960-6; discussion 966-7. 2006
    ..Rosiglitazone is a peroxisome proliferator-activated receptor gamma (PPARgamma) agonist that has been shown to induce differentiation, cell cycle arrest, and apoptosis in a variety of human cancers including thyroid cancer...
  8. ncbi Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations
    K A Woeber
    Department of Medicine, University of California, San Francisco Mount Zion, San Francisco 94143 1640, USA
    J Endocrinol Invest 25:106-9. 2002
    ....
  9. ncbi Extent of disease and practice patterns for medullary thyroid cancer
    Electron Kebebew
    Department of Surgery, University of California, San Francisco, San Francisco, CA 94143-1674, USA
    J Am Coll Surg 200:890-6. 2005
    ..A high proportion of patients continue to receive less than optimal initial surgical treatment...
  10. ncbi Methimazole-induced hepatotoxicity
    Kenneth A Woeber
    Department of Medicine, University of California, San Franscisco, California 94143-1640, USA
    Endocr Pract 8:222-4. 2002
    ..CONCLUSION: Physicians should be aware that thionamide drugs can be associated with hepatotoxicity. Analysis of the known cases suggests that older age of the patient and higher dose of the drug are risk factors for cholestatic injury...